100466-47-5

Basic information

• Product Name: N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline
• Synonyms: N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline
• CAS NO: 100466-47-5
• Molecular Weight: 227.349
• Mol File: 100466-47-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline(100466-47-5)
• EPA Substance Registry System: N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline(100466-47-5)

Safety Data

• Hazardous Substances Data: 100466-47-5(Hazardous Substances Data)

Upstream product

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 119-65-3 isoquinoline 
• 100466-46-4 N-benzyl-5,6,7,8-tetrahydroisoquinolinium bromide 

Downstream Products

• 89614-56-2 (S)-(+)-N-methyl-1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 125-73-5 (+)-dextrorphan 
• 30356-07-1 (1S)-1-[(4-methoxyphenyl)methyl]-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 100466-50-0 ((S)-1-tert-Butoxymethyl-2-methyl-propyl)-[1-[4a-(4-methoxy-benzyl)-4,4a,5,6,7,8-hexahydro-3H-isoquinolin-2-yl]-meth-(E)-ylidene]-amine 
• 100466-52-2 [1-((S)-1-Benzyl-3,4,5,6,7,8-hexahydro-1H-isoquinolin-2-yl)-meth-(E)-ylidene]-((S)-1-tert-butoxymethyl-2-methyl-propyl)-amine 
• 3882-38-0 dextromethorphan 
• 100466-53-3 (S)-N-methyl-1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 100466-51-1 (S)-1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 29144-31-8 (S)-2-Formyl-1-<(4-methoxyphenyl)methyl>-1,2,3,4,5,6,7,8-octahydroispquinoline 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia.

An asymmetric synthesis of (+)-morphinans in high enantiomeric purity

-